ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "SLE and interferons"

  • Abstract Number: 698 • 2019 ACR/ARP Annual Meeting

    Measurement of Type I IFNα Production at the mRNA Level and Its Potential Use as a Biomarker in Systemic Lupus Erythematosus

    Ilana Abeles1 and Vasileios Kyttaris 2, 1Beth Israel Deaconess Medical Center, Boston, MA, 2Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

    Background/Purpose: Gene expression studies have previously demonstrated increased Type I interferon α (IFN) inducible genes in peripheral blood mononuclear cells of systemic lupus erythematosus (SLE)…
  • Abstract Number: 1094 • 2018 ACR/ARHP Annual Meeting

    Endogenous Ifnβ Production Is Required for Efficient BCR Crosslinking and Survival of SLE B Cells

    John D. Mountz1, Shanrun Liu2, PingAr Yang3, Qi Wu4, Bao Luo5, W. Winn Chatham6 and Hui-Chen Hsu4, 1University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham, AL, 2Biochemistry & Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, 3Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 5Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 6Medcine/Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Increased type I interferon (IFN) has been shown to affect survival and activation of B cells in SLE. This study investigated novel mechanisms of…
  • Abstract Number: 1659 • 2017 ACR/ARHP Annual Meeting

    Identification of Long Noncoding RNA RP11-2B6.2 As a Positive Regulator through Type I Interferon Pathway in Lupus Nephritis

    Yuanjia Tang1, Zhuojun Liao1, Zhixin Xue1, Lingling Wu1 and Nan Shen1,2,3,4, 1Shanghai Institute of Rheumatology,Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) & Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, 4Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China

    Background/Purpose: Long noncoding RNAs (lncRNAs) have recently been identified to be tightly linked to diverse human diseases. Systemic lupus erythematosus (SLE) is a common autoimmune…
  • Abstract Number: 2575 • 2017 ACR/ARHP Annual Meeting

    The Role of Interferon in Autoimmune-Susceptible Ro60 Knockout Mice

    Masaoki Kawasumi1, Daiki Rokunohe1, Edward Chiou2, Xizhang Sun2, Lena Tanaka2, Sandra L. Wolin3 and Keith B. Elkon4, 1Medicine/Dermatology, University of Washington, Seattle, WA, 2Medicine/Rheumatology, University of Washington, Seattle, WA, 3RNA Biology Laboratory, National Cancer Institute, Frederick, MD, 4Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA

    Background/Purpose: The Ro60 protein is a prominent autoantigen in systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS). Anti-Ro antibodies are strongly associated with UV-mediated skin…
  • Abstract Number: 1082 • 2016 ACR/ARHP Annual Meeting

    Type I/II Interferon Commits to Abnormal Expression of Chemokine Receptor on B Cells in Patients with Systemic Lupus Erythematosus

    Maiko Yoshikawa1, Shingo Nakayamada2, Satoshi Kubo3, Shigeru Iwata4, Kei Sakata5, Yusuke Miyazaki3, Kazuhisa Nakano2, Kazuyoshi Saito6 and Yoshiya Tanaka7, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyusyu, Japan, 2First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 3The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 4First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 5Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan, 6University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 7University of Occupational and Environmental Health, Kitakyushu, Japan

    Background/Purpose:  Systemic lupus erythematosus (SLE) is characterized by an expanded population of peripheral memory B cells. However, little is known about the qualitative abnormality of…
  • Abstract Number: 1215 • 2016 ACR/ARHP Annual Meeting

    Interferon Signature Genes Are Differentially Expressed Between Microscopic Polyangiitis and Systemic Lupus Erythematosus Peripheral Blood Transcriptomes

    Aya Kawasaki1, Daisuke Tsukui2, Yuya Kondo3, Yoshitaka Kimura2, Kurumi Asako2, Hiroshi Furukawa1, Hajime Kono2, Takayuki Sumida4 and Naoyuki Tsuchiya1, 1Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 2Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 3Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan, 4Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

    Background/Purpose:  Interferon (IFN) signature has been established in the peripheral blood of the patients with systemic lupus erythematosus (SLE) by transcriptome analyses, indicating a role…
  • Abstract Number: 1827 • 2016 ACR/ARHP Annual Meeting

    Type I IFN Signature Low and High SLE Subjects with Moderate to Severe Disease Activity Have Distinct Gene Expression Signatures of Immunologic Pathways and Cell Types

    Hao Liu1, Brandon Higgs2, William Rees3, Chris Morehouse4, Katie Streicher5, P Brohawn2, G. Illei6 and K Ranade2, 1Translational Medicine, Medimmune, LLC, Gaithers, MD, 2MedImmune, Gaithersburg, MD, 3Translational Medicine, Medimmune, LLC, Gaithersburg, MD, 4Medimmune, LLC, Gaithers, MD, 5Translational Sciences, MedImmune, LLC, Gaithersburg, MD, 6Medimmune, Gaithersburg, MD

    Background/Purpose: Type I interferon (IFN) has been implicated in SLE pathogenesis, and the majority of subjects with SLE have elevated expression of type I IFN-inducible…
  • Abstract Number: 1615 • 2014 ACR/ARHP Annual Meeting

    MiR-127-3p As a Novel Regulator of Type I Interferon Signaling Pathway in SLE

    Bo Qu1,2, Xiao Han2 and Nan Shen1,2,3, 1Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China, 2Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) & Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, Shanghai, China, 3The Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States of America, Cincinnati, OH

    Background/Purpose Type I interferon(IFN) is a critical pathogenic factor in Systemic Lupus Erythematosus(SLE) and its associated nephritis, as elevated IFN inducible genes have been found…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences